论文部分内容阅读
对服用缓释剂长效盐酸二氢奎尼丁（Ｓｅｒｅｃｏｒ，赛利科）的８例健康者及３１例心律失常患者，采用反相高效液相色谱法检测血药浓度，用Ｈｏｌｔｅｒ评判疗效，以研究口服Ｓｅｒｅｃｏｒ后的药物动力学和药效学。研究表明：①健康者单剂量口服和心律失常患者多剂量口服达稳态时药－时曲线均符合一室开放模型。②口服Ｓｅｒｅｃｏｒ后，抗室性和房性心律失常的总有效率分别为８８．９％和７５．０％，慢性心房颤动（简称房颤）的复律成功率为５０．０％。最低平均有效血药浓度：抗室性心律失常为０．７１μｇ／ｍｌ、抗房性心律失常为１．１６μｇ／ｍｌ、慢性房颤复律为１．９２μｇ／ｍｌ。发生促心律失常作用的血药浓度为２．２９μｇ／ｍｌ。不良反应发生率为３２．３％，其中以胃肠道反应多见。结论：口服Ｓｅｒｅｃｏｒ后吸收较快，稳态时药－时曲线稳定性和缓和性均较理想，每１２ｈ给药一次的方式是合理的。Ｓｅｒｅｃｏｒ对室性和房性心律失常均有效，但抗室性心律失常疗效优于房性心律失常。
Eight healthy subjects and 31 patients with arrhythmia who took slow-acting long-acting serecoride hydrochloride were detected by reversed-phase high-performance liquid chromatography (HPLC) To study the pharmacokinetics and pharmacodynamics after oral Serecor. The results showed that: (1) The time-dose curve of oral administration of multi-dose orally and arrhythmia patients in healthy subjects was consistent with the one-compartment open model. ② After oral Serecor, the total effective rates of anti-ventricular and atrial arrhythmia were 88.9% and 75.0% respectively, and the success rate of cardioversion of chronic atrial fibrillation (atrial fibrillation) was 50.0%. The lowest mean effective plasma concentration: anti-ventricular arrhythmia was 0.71μg / ml, anti-arrhythmia 1.16μg / ml, chronic atrial fibrillation complex was 1.92μg / ml. Prothrombin function of the blood concentration of 2.29μg / ml. The incidence of adverse reactions was 32.3%, of which gastrointestinal reactions more common. Conclusion: After oral Serecor absorption faster, steady-state drug-time curve stability and mitigation are more ideal, the method of administration once every 12h is reasonable. Serecor is effective in both ventricular and atrial arrhythmias, but anti-ventricular arrhythmias are superior to atrial arrhythmias.